AR and prostate carcinoma: ✓an androgen receptor (AR) antagonist (IC50 = 160 nM) ✓reduces p-RPS6 (S235/236) by inhibiting DHT-stimulated mTORC1 activity in an AR-mediated manner in LNCaP prostate cancer cells [207]